COMMUNIQUÉS West-GlobeNewswire

Neovacs to host KOL Meeting to discuss its therapeutic vaccin IFNalpha Kinoid for lupus treatment - February 11th Paris
05/02/2019
NEOVACS TO HOST KOL MEETING TO DISCUSS ITS THERAPEUTIC VACCINE IFN α KINOID FOR LUPUS TREATMENT FEBRUARY 11, 2019 – 17h00 Hôtel Renaissance Le Parc Trocadéro – Paris Paris and Boston, February 5 th 2019 – 7h30 CET - [...]
Néovacs organise une réunion KOL concernant son vaccin thérapeutique IFNalpha Kinoïde pour le traitement du lupus - 11 février à Paris
05/02/2019
NÉOVACS ORGANISE UNE RÉUNION KOL CONCERNANT SON VACCIN THÉRAPEUTIQUE IFNα KINOÏDE POUR LE TRAITEMENT DU LUPUS 11 FÉVRIER 2019 – 17h00 Hôtel Renaissance Le Parc Trocadéro - Paris Paris et Boston, le 5 février 2019 – 7h30 [...]
Sanofi : Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma
05/02/2019
Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma Study evaluated the benefit of isatuximab in combination with standard of [...]
Sanofi : L'essai de phase III consacré à l'isatuximab a atteint son critère d'évaluation principal de prolongation de la survie sans progression chez des patients atteints d'un myélome multiple ré...
05/02/2019
L'essai de phase III consacré à l'isatuximab a atteint son critère d'évaluation principal de prolongation de la survie sans progression chez des patients atteints d'un myélome multiple récidivant/réfractaire L'essai a [...]
Idorsia announces the first patient recruited into REACT - the Phase 3 registration study with clazosentan
05/02/2019
REACT assesses the efficacy and safety of intravenous clazosentan for the prevention of clinical deterioration due to vasospasm-related delayed cerebral ischemia following aneurysmal subarachnoid hemorrhage (aSAH) On [...]
GENFIT: Reports Full-Year 2018 Financial Results: cash position of €207.2m as of 12.31.2018
05/02/2019
GENFIT: Reports Full-Year 2018 Financial Results: cash position of €207.2m as of 12.31.2018 GENFIT achieved significant development milestones in 2018: Completed enrollment of interim analysis cohort for phase 3 RESOLVE [...]
GENFIT : Résultats financiers 2018 : Trésorerie de clôture de 207.2m€ au 31.12.2018
05/02/2019
GENFIT : Résultats financiers 2018 : Trésorerie de clôture de 207.2m€ au 31.12.2018 Étapes décisives franchies par GENFIT en 2018 : achèvement du recrutement de la cohorte d'analyse intermédiaire de l'essai de phase 3 [...]
Veritas Pharma to Proceed with Share Consolidation
05/02/2019
VANCOUVER, British Columbia, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) announces that it is proceeding with a consolidation of its [...]
The Ensign Group Schedules Year-End 2018 Earnings Call for Thursday, February 7, 2019
05/02/2019
MISSION VIEJO, Calif., Feb. 04, 2019 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of skilled nursing, rehabilitative care services, assisted living, home health, [...]
REVA Announces Reduction in Force
05/02/2019
SAN DIEGO, Feb. 04, 2019 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, announced it is realigning the organization [...]
PRA Health Sciences to Report Fourth Quarter 2018 Earnings
04/02/2019
RALEIGH, N.C., Feb. 04, 2019 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its fourth quarter and year end 2018 results after the market closes on Wednesday, February 27, 2019. The Company [...]
Surface Oncology Retains Worldwide Rights for its First-in-Class Antibody Targeting IL-27, SRF388
04/02/2019
IL-27 is a key regulator of checkpoint protein expression SRF388 believed to be the only anti-IL-27 targeted agent in late-preclinical development Investigational New Drug (IND) submission for SRF388 expected in Q4 2019 [...]
OPKO Health, Inc. Announces Proposed Offering of Convertible Senior Notes
04/02/2019
MIAMI, Feb. 04, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (“OPKO Health” or the “Company”) (NASDAQ: OPK) today announced that, subject to market and other conditions, it intends to offer $200 million aggregate [...]
Prothena to Report Fourth Quarter and Full Year 2018 Financial Results and Host Webcast Conference Call on February 14
04/02/2019
DUBLIN, Ireland, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, announced today that it will report its fourth quarter and full year 2018 financial [...]
Codexis Secures Multi-Year Technology Upgrade Package for its CodeEvolver Protein Engineering Platform License with Merck
04/02/2019
REDWOOD CITY, Calif., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces the signing of a new agreement with Merck, through a subsidiary. Under the terms of [...]
DBV Technologies to Present Data on Epicutaneous Immunotherapy at AAAAI 2019
04/02/2019
Montrouge, France, February 4, 2019 DBV Technologies to Present Data on Epicutaneous Immunotherapy at AAAAI 2019 Novel immunotherapy based on Viaskin technology highlighted as a potential treatment for food-allergic [...]
DBV Technologies présentera des données sur l'immunothérapie épicutanée au congrès de l'AAAAI 2019
04/02/2019
Montrouge, France, le 4 février (22 :00 CET) 2019 DBV Technologies présentera des données sur l'immunothérapie épicutanée au congrès de l'AAAAI 2019 L'immunothérapie innovante de DBV, reposant sur la technologie Viaskin [...]
VIVUS Announces Date of 2019 Annual Meeting
04/02/2019
CAMPBELL, Calif., Feb. 04, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that the Company will hold its 2019 Annual Meeting of Stockholders (the “2019 [...]
Generex Biotechnology Responds to Demand for Payment
04/02/2019
- Challenges notice from Alpha Capital MIRAMAR, FL, Feb. 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB: GNBT) ( http://www.otcmarkets.com/stock/GNBT/quote [...]

Pages